Summary
Magnesium has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Osteoporosis. ClinicalTrials.gov lists 8 registered trials linking Magnesium to Osteoporosis: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT02629341). The largest enrolment is 115 participants (NCT06135831). Registration activity spans 2002 to 2019. The literature layer holds 12 publications for this pair: 4 Cochrane reviews, 2 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2006 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Osteoporosis ranks 221 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Bone density decline of 1-3%/year in postmenopausal women without treatment; fracture risk increases exponentially with T-score decline; no spontaneous remission.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 55.5 (trials 20.5, literature 30.0, tier 5, approved bonus 0.0) |
| Registered trials | 8 total: 0 recruiting, 0 active / not yet recruiting, 6 completed, 2 other |
| Linked publications | 12 (5 clinical trial publications, 4 Cochrane reviews, 2 meta-analyses, 1 systematic review) |
| Agent type | Supplement |
| Development stage (any indication) | Preclinical |
| Mechanism / class | Herbal and nutraceutical interventions for osteoporosis: a review of effects on bone mineral density · Halma M, O'Leary C, Varon J · 2025 |
| Data sources | OSMF Chronic Disease Review |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT02629341 | Functional Yogurt Powder Effect on Bone Health Biomarkers 2015 | completed | Phase 3 | 79 |
| NCT03812380 | Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate 2019 | terminated | Phase 3 | 62 |
| NCT00346658 | Magnesium Supplementation to Prevent Bone Loss 2002 | completed | Phase 1 | 74 |
| NCT01971411 | Vitamin D Deficiency in Elderly African American Women in Central Texas 2006 | completed | Not applicable | 60 |
| NCT01881204 | Hesperidin and Bone Health in Postmenopausal Women 2011 | completed | Not applicable | 12 |
| NCT06135831 | Effect of Consumption of Supplements and Enriched Olive Paste on Bone Metabolism Indices 2019 | completed | Not applicable | 115 |
| NCT05025917 | Assessing the Effect of Shatavari Supplementation on Bone and Skeletal Muscle Health in Healthy Postmenopausal Women 2019 | completed | Not applicable | 24 |
| NCT01131884 | Pilot Study of Fosamax in Spinal Cord Injury 2010 | terminated | Not applicable | 1 |
Published literature
- Clinical trial publication Quantitative sensory testing of pain in osteoporosis: a pilot randomized clinical trial with magnesium supplementationPickering ME, Morel V, Nicolas M et al. · Aging clinical and experimental research · 2026 · PMID 41566091
- Systematic review Proton pump inhibitors, bone and phosphocalcic metabolismPhilippoteaux C, Paccou J, Chazard E et al. · Joint bone spine · 2024 · PMID 38458487
- Cochrane review Impact of magnesium on bone health in older adults: A systematic review and meta-analysisGroenendijk I, van Delft M, Versloot P et al. · Bone · 2022 · PMID 34666201
- Meta-analysis Genetically Predicted Milk Intake Increased Femoral Neck Bone Mineral Density in Women But Not in MenChen S, Zheng C, Chen T et al. · Frontiers in endocrinology · 2022 · PMID 35795146
- Clinical trial publication Effect of vitamin K2 and vitamin D3 on bone mineral density in children with acute lymphoblastic leukemia: a prospective cohort studySolmaz I, Ozdemir MA, Unal E et al. · Journal of pediatric endocrinology & metabolism : JPEM · 2021 · PMID 33639045
- Clinical trial publication A Dairy Product to Reconstitute Enriched with Bioactive Nutrients Stops Bone Loss in High-Risk Menopausal Women without Pharmacological TreatmentMorato-Martínez M, López-Plaza B, Santurino C et al. · Nutrients · 2020 · PMID 32722015
- Clinical trial publication Efficacy and safety of a fixed-dose combination of nimesulide/pantoprazole compared to naproxen/esomeprazole for pain relief in patients with osteoarticular diseases and dyspeptic symptomsScheinberg M, Pott Júnior H, Macêdo EA et al. · Drug design, development and therapy · 2018 · PMID 30233140
- Clinical trial publication Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women: a randomized controlled trialLambert MNT, Thybo CB, Lykkeboe S et al. · The American journal of clinical nutrition · 2017 · PMID 28768651
- Cochrane review Use of ossein-hydroxyapatite complex in the prevention of bone loss: a reviewCastelo-Branco C, Dávila Guardia J · Climacteric : the journal of the International Menopause Society · 2015 · PMID 24893923
- Meta-analysis Association between serum level of magnesium and postmenopausal osteoporosis: a meta-analysisZheng J, Mao X, Ling J et al. · Biological trace element research · 2014 · PMID 24728877
- Cochrane review A review of select vitamins and minerals used by postmenopausal womenDennehy C, Tsourounis C · Maturitas · 2010 · PMID 20580500
- Cochrane review Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trialsWhelan AM, Jurgens TM, Bowles SK · The Annals of pharmacotherapy · 2006 · PMID 16670364
Mechanism and notes
Recorded mechanism or class: Herbal and nutraceutical interventions for osteoporosis: a review of effects on bone mineral density · Halma M, O'Leary C, Varon J · 2025.
OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Magnesium approved for Osteoporosis?
Magnesium has reached Preclinical as its most advanced recorded development stage across any indication, and the database holds no approval for Osteoporosis. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Magnesium in clinical trials for Osteoporosis?
ClinicalTrials.gov lists 8 registered trials linking Magnesium to Osteoporosis: 6 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT02629341). The largest enrolment is 115 participants (NCT06135831). Registration activity spans 2002 to 2019.
What does the evidence show for Magnesium in Osteoporosis?
Magnesium has both completed registered trials and synthesis-level publications linked to Osteoporosis. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is C (Preliminary), derived from the strength of the disease association recorded in OSMF Chronic Disease Review. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.